Q3 EPS Forecast for Vertex Pharmaceuticals Raised by Analyst

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Research analysts at Zacks Research upped their Q3 2025 EPS estimates for Vertex Pharmaceuticals in a research note issued to investors on Tuesday, December 24th. Zacks Research analyst R. Department now anticipates that the pharmaceutical company will post earnings of $4.01 per share for the quarter, up from their prior forecast of $3.99. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.83) per share.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. Vertex Pharmaceuticals’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm earned $3.67 EPS.

A number of other equities research analysts also recently weighed in on the stock. Morgan Stanley upped their price target on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. cut their target price on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, December 23rd. Citigroup began coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 14th. They set a “buy” rating and a $575.00 target price on the stock. Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the stock from $500.00 to $550.00 in a report on Monday, December 9th. Finally, UBS Group upped their price objective on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $494.04.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $408.76 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The stock has a market cap of $105.27 billion, a price-to-earnings ratio of -205.41 and a beta of 0.36. The stock’s 50 day moving average price is $462.47 and its 200 day moving average price is $472.68. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88.

Institutional Trading of Vertex Pharmaceuticals

A number of institutional investors have recently bought and sold shares of VRTX. Northwest Investment Counselors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth $25,000. Dunhill Financial LLC increased its stake in shares of Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 24 shares during the last quarter. Highline Wealth Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at approximately $27,000. GHP Investment Advisors Inc. acquired a new position in Vertex Pharmaceuticals during the second quarter valued at approximately $29,000. Finally, Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals in the third quarter valued at approximately $33,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.